How does niaspan er work

Tablets not shown actual size. NIASPAN has been shown to reduce the chance of having another heart attack in patients who have a prior history of heart attack and have high cholesterol. Plaque buildup fatty deposits is a complex process related to a number of risk factors, including a family history of early heart disease, high blood pressure, smoking, diabetes, and abnormal cholesterol levels.

NIASPAN can help slow plaque buildup and even help clear plaque from artery walls when used in combination with a low-cholesterol diet and a bile acid-binding resin another cholesterol medication in patients with a history of coronary artery disease and high cholesterol.

NIASPAN, combined with a bile acid-binding resin, has not been shown to prevent heart disease, heart attacks, or stroke. NIASPAN and other medicines including vitamins and herbal supplements can react with each other and may cause side effects. Tell your doctor about all the prescription and non-prescription medicines you take, including:.

Taking NIASPAN with another cholesterol-lowering medicine simvastatin does not reduce heart attacks or strokes more than taking simvastatin alone. References: 1. NIH publication No. Published December Tablets not shown actual size. NIASPAN and other medicines including vitamins and herbal supplements can react with each other and may cause side effects.

Tell your doctor about all the prescription and non-prescription medicines you take, including:. Taking NIASPAN with another cholesterol-lowering medicine simvastatin does not reduce heart attacks or strokes more than taking simvastatin alone. References: 1. Mayo Clinic. Published April 15, Accessed October 5, Statins vs. Am J Clin Nutr. Aspirin was used by one third of patients before Niaspan dosing to minimize flushing episodes.

Adverse events in general varied widely, but their true relation to the study drug is difficult to ascertain without a placebo control group. No deaths occurred. Niacin nicotinic acid favourably modifies all aspects of the lipoprotein profile; it raises high-density lipoprotein cholesterol HDL-C levels, lowers triglyceride, low-density lipoprotein cholesterol LDL-C and lipoprotein a levels and reduces atherogenic small, dense LDL particles.

One large monotherapy trial and multiple trials of niacin in combination with other lipid-modifying drugs show remarkable consistency in the ability of niacin to improve angiographic and clinical outcomes.